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Abstract. Metastatic dissemination of the primary tumor 
is the major cause of death in colorectal cancer (CRC) 
patients. Multiple chromosomal breaks and chromothripsis, a 
phenomenon involving multiple chromosomal fragmentations 
occurring in a single catastrophic event, are associated with 
cancer genesis, progression and developing of metastases. The 
aim of this study was to evaluate the effect of chromothripsis 
and total breakpoint count (breakpoint instability index) 
on progression-free survival (PFS). A total of 19 patients 
with metastatic CRC (mCRC) receiving FOLFOX first‑line 
palliative chemotherapy between August, 2011 and October, 
2012 were selected for this study. The results indicated that 
the highest breakpoint count was observed in chromosomes 
1, 2 and 6. Chromothripsis was detected in 52.6% of the study 
patients. Furthermore, chromothripsis was associated with an 
increased median PFS (mPFS; 14 vs. 8 months, respectively; 
P=0.03), but an association with overall survival was not iden-
tified. The present study demonstrated that chromothripsis 
affected CRC patient survival, suggesting a role for this event 
as a prognostic and predictive marker in mCRC treatment.
Introduction
Mortality from colorectal cancer (CRC) has decreased over 
the past 30 years; however, there is a significant heterogeneity 
in survival rates that may be mainly explained by variations 
in patient and tumor characteristics, host response factors 
and applied treatment modalities. At the time of diagnosis, 
~25% of the patients have already developed metastases and 
~50% will develop metastases following treatment of the 
primary CRC (1).
During cancer development, the cells acquire multiple point 
mutations and chromosomal rearrangements. Chromosomal 
abnormalities that are found in primary CRC cells are gains of 
8q, 11q, 13q and 20q and losses of 1p, 4, 8p, 17p, 18q and 22q 
chromosomal regions (2-5).
Van den Broek et al reported a clinical relevance of 
chromosomal breaks in metastatic CRC (mCRC) in 2015; 
they identified 1605 genomic breakpoint locations and 748 
breakpoint genes with recurrence in multiple CRC samples. 
None of the individual breakpoint genes was significantly 
associated with overall survival (OS), but four CRC subtypes 
were revealed based on recurrent breakpoint genes and muta-
tion status of commonly affected CRC genes [adenomatous 
polyposis coli, tumor protein p53, Kirsten rat sarcoma viral 
oncogene homolog (KRAS), phosphatidylinositol-4,5-bispho-
sphate 3-kinase catalytic subunit α, B-Raf proto-oncogene, 
serine/threonine kinase, neuroblastoma RAS viral oncogene 
homolog, mothers against decapentaplegic homolog 4 and 
F-box/WD repeat-containing protein 7] (6).
Chromothripsis, a massive chromosome fragmentation 
occurring in one catastrophic event, is observed in 2-3% of 
cancers (7). Such genomic rearrangements may drive the 
development of cancer through several mechanisms, including 
deletion of tumor suppressor genes and increased copy number 
of oncogenes. The prevalence of chromothripsis and its effect 
on prognosis and metastasis is unclear. The incidence of chro-
mothripsis ranges from 1.3% in multiple myeloma (8) to 33% in 
osteosarcoma (7). Furthermore, chromothripsis has been associ-
ated with poor patient survival in the aggressive triple-negative 
subtype of breast cancer, multiple myeloma and pediatric 
medulloblastoma (8-10), indicating its potential relevance as a 
prognostic marker, and suggesting chromothripsis to be a char-
acteristic of certain particularly aggressive types of cancer.
The incidence of chromothripsis and its effect on survival 
in CRC is unclear, but it may be a prevalent genomic rear-
rangement in this type of cancer (11).
Patients and methods
Study population. A total of 19 mCRC patients who received 
chemotherapy at the Clinic of Oncology of Pauls Stradins 
Clinical University Hospital (Riga, Latvia) between August, 
2011 and October, 2012 were selected. The study was 
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performed with approval from the Ethics Committee of the 
Riga Stradins University and written informed consent was 
obtained from all the patients who were investigated. Tissue 
samples were acquired as part of a series of routine diagnostic 
and pathological analyses at the hospital. The patients were 
followed up for 3-48 months.
The clinical and biological characteristics of the patients 
are summarized in Table I. Of the 19 patients, 15 had primary 
metastatic cancer (stage IV), whereas the 4 remaining patients 
developed metastases after treatment of the primary cancer. 
A total of 10 patients developed metastases only to the liver; 
16 patients underwent primary tumor surgery, whereas in 
3 patients biopsy alone was performed. In 7 patients, the 
carcinoembryonic antigen (CEA) level was ≤5.5 ng/ml prior 
to chemotherapy.
A total of 18 patients received FOLFOX first‑line chemo-
therapy (1 patient declined chemotherapy). After disease 
progression, 13 patients received irinotecan-containing 
second-line chemotherapy, 1 patient was rechallenged with 
FOLFOX, 1 patient received oral fluoropyrimidine therapy 
with Ftorafur (tegafur) and 1 patient received best supportive 
care. Only 5 patients (26.3%) received third-line therapy 
[irinotecan, oxaliplatin or 5‑fluorouracil (5FU)]. One patient 
underwent hepatic surgery for CRC metastases after discon-
tinuation of second-line chemotherapy, 2 patients received 
salvage transcatheter arterial chemoembolization of CRC liver 
metastases by irinotecan-eluting microspheres, and 1 patient 
received palliative radiotherapy for local rectal cancer. Data 
on clinical follow-up were obtained until August, 2016.
Genotyping. DNA was extracted from formalin-fixed 
paraffin-embedded (FFPE) samples with QIAamp DNA 
Mini kit (Qiagen, Hilden, Germany) according to the 
Table I. Clinical and biological characteristics of the patients 
(n=19).
Characteristics No. (%)
Age, years [mean (range)] 63.15 (38-78)
Gender
  Male 11 (57.89)
  Female 8 (42.11)
Tumor localization
  Left side (sigmoid colon, rectal cancer) 11 (57.89)
  Right side (colon cancer) 8 (42.11)
Grade
  Unknown 1 (5.26)
  G2 13 (68.42)
  G3 5 (26.32)
Metastases
  Synchronous 15 (78.95)
  Metachronous (median time 4 (21.05)
  tometastasis, 12.25 months; range,
  9-18 months)
  Stage II (n=3)
  Stage III (n=1)
Metastases
  Liver only 10 (52.63)
  Other 9 (47.37)
KRAS status in primary tumor
  Wild-type 10 (52.64)
  Mutation in 12 codon 7 (36.84)
  Mutation in 13 codon 1 (5.26)
  Not known 1 (5.26)
Serum CEA prior to chemotherapy
  CEA ≤5.5 ng/ml 7 (36.84)
  CEA >5.5 ng/ml 12 (63.16)
  Level of CEA, ng/ml [mean (range)]  232.1 (7.1959.8)
Median follow-up (months) 25.5 (348)
mPFS 8 months
  1-year 33.3%
  2-year  5.6%
mOS 21 months
  1-year 78.9%
  2-year 42.1%
  3-year  21.1%
CEA, carcinoembryonic antigen; KRAS, Kirsten rat sarcoma viral 
oncogene homolog; mPFS, median progression-free survival; mOS, 
median overall survival.
Table II. Chromosomes affected by chromothripsis and total 
breakpoint count per chromosome.
 Breakpoint no., Chromothripsis,
Chromosome range (median) no. of patients (%)
  1 27-365 (150.2) 10 (52.6)
  2 25-315 (136.8) 10 (52.6)
  3 21-234 (94.5) 7 (36.8)
  4 10-232 (73.9) 5 (26.3)
  5 20-189 (87.1) 5 (26.3)
  6 22-298 (118.9) 10 (52.6)
  7 16-195 (82.7) 5 (26.3)
  8 16-199 (81.6) 5 (26.3)
  9 11-205 (79.2) 5 (26.3)
10 21-275 (106.8) 7 (36.8)
11 34-252 (104.1) 8 (42.1)
12 18-206 (84.2) 6 (31.6)
13 14-166 (54.1) 3 (15.8)
14 12-152 (58.6) 4 (21.1)
15 3-166 (58.9) 4 (21.1)
16 9-158 (60.5) 4 (21.1)
17 10-206 (66.8) 4 (21.1)
18 10-149 (50.5) 2 (10.5)
19 7-137 (44.2) 2 (10.5)
20 9-124 (42.3) 2 (10.5)
21 7-99 (24.7) 0 (0.0)
22 4-131 (37) 1 (5.3)
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manufacturer's instructions. Quality was evaluated using the 
Illumina FFPE QC kit (Illumina, San Diego, CA, USA) by 
reverse transcription-polymerase chain reaction. DNA was 
restored with the Illumina DNA restoration kit (Illumina). 
Microarray analysis was performed using the Infinium 
HumanOmniExpress-12 v1.0 FFPE BeadChip kit (Illumina). 
BeadChip was scaned on HiScan (Illumina). Analysis 
was performed by GenomeStudio software (Illumina) and 
R version 3.1.2. (https://www.r-project.org/). Copy number 
variation and breakpoints on the chromosomes were analyzed 
Figure 1. Multiple chromosome 1 fragmentation (chromothripsis). There were multiple deletions in both arms of chromosomes 1 and 2 in patient 14. Chr, 
chromosome; CN, copy number. 
Figure 2. Similar pattern of chromosomal rearrangements of chromosome 3 in four different patients (patients 3, 8, 9 and 14). Chr, chromosome; CN, copy 
number.
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using the DNA copy package (http://bioconductor.org/pack-
ages/release/bioc/html/DNAcopy.html).
OS and progression-free survival (PFS) rates were estimated 
using the Kaplan-Meier method. The log-rank test was used to 
calculate any significant difference between the subgroups by 
univariate analysis. Significance levels were set at P<0.05. All 
statistical analyses were performed using MedCalc software, 
version 16.4.8 (MedCalc Software, Ostend, Belgium).
Results
Breakpoint count per chromosome. The aim of this study 
was to evaluate the total number of chromosomal breaks and 
association of chromothripsis (>100 breakpoints detected in 
one chromosome) with PFS in mCRC. The total number of 
breakpoints per genome in cancer tissue [breakpoint instability 
index (BPI)] was 368-4,009. The highest breakpoint count was 
seen in chromosome 1 (27-365 breakpoints), followed by chro-
mosome 2 (25-315) (Table II), indicating the crucial role of 
these chromosomes in CRC development. The lowest density 
of breaks occurred in chromosome 21 (7-99 breakpoints; 
Fig. 1). Of note, a similar pattern of chromosomal rearrange-
ments was observed in several patients for chromosomes 1, 3 
and 8 (Fig. 2).
In 10 of the tumor samples (52.6%), multiple chromosomal 
fragmentations were found, found, referred to as chro-
mothripsis, a recently reported catastrophic genetic event. The 
most commonly affected chromosomes were chromosomes 1, 
2 and 6 (52.6% of the patients; Table II). The maximal count of 
chromosomes affected by chromothripsis was 20, which was 
observed in 1 patient.
Association of breakpoint number with clinicopathological 
characteristics. No association of BPI value and chro-
mothripsis with cancer localization (rectal or colon cancer), 
CEA level, KRAS mutational status in primary cancer and 
stage [synchronous metastatic disease (stage IV) vs. metachro-
nous metastatic disease] was observed.
Association of breakpoint number with survival. PFS and OS 
were measured for all the patients in study. Decreased PFS 
was observed in patients with left-sided metastatic cancer 
(sigmoid colon and rectal cancer), elevated CEA level prior to 
chemotherapy (Fig. 3A) and KRAS mutations.
A positive correlation between high BPI (chromothripsis) 
and increased PFS was observed (Fig. 3B and C). Due to 
the observed better PFS in different clinical subgroups by 
CEA, KRAS status and primary tumor location, the effect 
of BPI and chromothripsis on clinical findings was analyzed; 
however, the number of patients in each subgroup was insuf-
ficient to establish a statistically significant correlation. In 
patients with detected chromothripsis and CEA ≤5.5 ng/ml 
(n=4), a median PFS (mPFS) of 22.5 months was observed; in 
patients without chromothripsis and elevated CEA level (n=7), 
an mPFS of 8 months was observed, but these findings did not 
reach statistical significance. A statistically significant effect 
of any clinical or biological factors on OS was not observed.
Discussion
The effect of chromosomal rearrangements and mutations on 
pathogenesis, prognosis and resistance to treatment are widely 
described in mCRC studies. The prognostic and predictive role 
of breakpoint instability index and chromothripsis remains 
unclear.
In the present study, a correlation between massive DNA 
fragmentation (chromothripsis) and PFS in mCRC was 
observed. As opposed to recent studies suggesting chro-
mothripsis to be associated with worse prognosis, we found 
chromothripsis to be a positive predictive factor for first‑line 
chemotherapy. It may be hypothesized that cancer cells exhib-
iting radical DNA rearrangements, such as chromothripsis, are 
more sensitive to nucleic acid-damaging therapy with 5FU and 
oxaliplatin.
Breakpoint instability index was previously reported in 
breast cancer study by Przybytkowski et al (10); they reported 
a BPI of 25-300 in breast cancer tissue, with the highest density 
of breaks in chromosome 17 and the lowest density in chromo-
some 4. The BPI appeared to be different in different breast 
cancer molecular subtypes, with the highest breakpoint count 
in aggressive triple-negative breast cancer. In comparison, in 
our study on CRC tissue, the highest breakpoint density was 
found in chromosomes 1 and 2 and the lowest in chromo-
some 21, but the BPI was significantly higher (368‑4,009). In 
Figure 3. (A) mPFS in elevated CEA: 8 months; mPFS in CEA ≤5.5 ng/ml: 14 months; HR=0.29. (B) mPFS for BPI ≥1,400: 14 months; mPFS for BPI <1,400: 
8 months; HR=3.43. (C) mPFS in cases exhibiting chromothripsis (+): 14 months; mPFS in cases without chromothripsis (-): 8 months; HR=3.43. mPFS, median 
progression-free survival; CEA, carcinoembryonic antigen; BPI, breakpoint instability index; HR, hazard ratio.
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addition, 10 tumor samples (52.6%) exhibited a chromothripsis 
pattern on ≥3 chromosomes, which was higher compared 
with previous reports (7,8,10). The high BPI value and high 
prevalence of chromothripsis in our study may be attributed to 
the fact that all the patients had late-stage metastatic disease, 
which is consistent with the prevalence of chromothripsis 
reported in high-risk aggressive tumors.
In conclusion, the present study demonstrated that chro-
mothripsis is associated with increased PFS, but not with OS in 
mCRC. Further studies with larger sample sizes are required to 
determine whether chromothripsis and BPI value may be used 
as a prognostic or predictive factor for oxaliplatin-containing 
first‑line chemotherapy for mCRC.
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